Brian Bird, MD
Ophthalmology · South Jordan, UTNPI 1023645090
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,553 of the $5,569 with a category attached, or 81.8%. Sun Pharmaceutical Industries Inc. accounts for 81.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $5,009 and has fallen 89.2% since, to $540 in 2025.
Across 28 payments — averaging $198.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$5K
- Alcon$304
- Biotissue Holdings Inc.$193
- Bausch & Lomb Americas Inc.$159
- Harrow Eye, LLC$112
- Glaukos Corporation$90
- plus $159 from 4 others
What the payments were for
- Speaking & faculty fees$4,55382%
- Food & beverage$1,01618%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 1 | $4,553 |
| Alcon | 7 | $304 |
| Biotissue Holdings Inc. | 4 | $193 |
| Bausch & Lomb Americas Inc. | 3 | $159 |
| Harrow Eye, LLC | 2 | $112 |
| Glaukos Corporation | 4 | $90 |
| Tarsus Pharmaceuticals, Inc. | 3 | $66 |
| Rxsight Inc | 2 | $40 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $28 |
| Johnson & Johnson Vision Care, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$4,553
- Voyager DSLT$127
- MIEBO$125
- XIIDRA$125
How this compares
$5,569 in reported general payments places this provider in the 85th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 14 | $1,095 |
| Latanoprost | 33 | $347 |
| MoxifloxacinMoxifloxacin Hcl | 14 | $311 |
| Ketorolac Tromethamine | 12 | $274 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $126 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in South Jordan
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Ron LordSt. George$61K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Phillip HoopesDraper$26K
- Sharon RichensSt George$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.